Skip to main content

Table 2 Chemotherapy regimens

From: Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study

Regimen n = 36
SCLC n = 9
 CDDP/CBDCA + VP-16 4
 NGT 2
 AMR 3
NSCLC (EGFR mutation wild type) n = 22
 CBDCA + PAC + BEV 2
 CBDCA + PAC 4
 CBDCA + nab-PAC 1
 CDDP/CBDCA + PEM 7
 PEM 3
 DOC 5
NSCLC (EGFR mutation sensitive) n = 5
 gefitinib 2
 erlotinib 3
  1. Abbreviations: EGFR epidermal growth factor receptor, SCLC small cell lung cancer, NSCLC non-small cell lung cancer, CDDP cisplatin, CBDCA carboplatin, VP-16 etoposide, NGT nogitecan, AMR amrubicin, PAC paclitaxel, BEV bevacizumab, nab-PAC albumin-binding paclitaxel, PEM pemetrexed, DOC docetaxel